Ivabradina Chemo Ibérica (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this inward sodium/potassium current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a reduced heart‑rate without affecting contractility or blood pressure.

The dose of Ivabradina Chemo Ibérica is determined by the prescribing clinician based on the patient’s clinical status, heart‑rate targets, and tolerance. Dosage adjustments may be required after assessing heart‑rate response and any adverse effects.

Safety data for ivabradine in pregnancy and lactation are limited, and the product is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk. Clinicians should discuss alternatives and risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors. This means it does not influence contractility or blood pressure as beta‑blockers do, making it useful for patients who cannot tolerate beta‑blockade.

Ivabradina Chemo Ibérica should be stored at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight to maintain stability.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber provides specific instructions.

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and worsening angina that could lead to myocardial infarction. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradina Chemo Ibérica is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block, uncontrolled hypotension, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.